Entera Bio Ltd. R&D Expenses

R&D Expenses of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including R&D Expenses growth rates and interactive chart. Research and development (R&D) expenses are associated with the research and development of a company's goods or services. A company generally incurs R&D expenses in the process of finding and creating new products or services. It is an operating expense and can be deducted from a company's income taxes.

Highlights and Quick Summary

  • R&D Expenses for the quarter ending June 29, 2020 was $2.01 Million (a 25.3% increase compared to previous quarter)
  • Year-over-year quarterly R&D Expenses increased by 12.6%
  • Annual R&D Expenses for 2019 was $7.2 Million (a -15.48% decrease from previous year)
  • Annual R&D Expenses for 2018 was $8.52 Million (a 207.73% increase from previous year)
  • Twelve month R&D Expenses ending June 29, 2020 was $7.37 Million (a 8.83% increase compared to previous quarter)
  • Twelve month trailing R&D Expenses increased by 1.08% year-over-year
Trailing R&D Expenses for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$7.37 Million $6.77 Million $7.2 Million $7.29 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical R&D Expenses of Entera Bio Ltd.

Most recent R&D Expensesof ENTX including historical data for past 10 years.

Interactive Chart of R&D Expenses of Entera Bio Ltd.

Entera Bio Ltd. R&D Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $2.01 $1.61
2019 $1.97 $1.79 $1.41 $2.04 $7.2
2018 $2.05 $1.81 $1.77 $2.89 $8.52
2017 $2.77

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.